» Articles » PMID: 15889354

Relatively Poor Outcome After Treatment of Clostridium Difficile Colitis with Metronidazole

Overview
Journal Clin Infect Dis
Date 2005 May 13
PMID 15889354
Citations 145
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clostridium difficile is a frequent cause of serious nosocomial infection. Earlier reports have suggested that treatment with metronidazole cured nearly 90% of patients, with only a modest rate of recurrence of infection. In recent years, the rate of response to treatment with this drug has appeared to be much lower.

Methods: We undertook a prospective, observational study of 207 patients who were treated with metronidazole for C. difficile colitis.

Results: A total of 103 patients (50%) were cured by the initial course of therapy and had no recurrence of disease. Forty-six patients (22%) continued to have symptoms of colitis for > or = 10 days despite treatment, and 58 (28%) responded initially but had a recurrence within the ensuing 90 days. The mortality rate among patients who developed C. difficile colitis was 27%, and it was higher among patients who did not respond fully to an initial course of therapy, compared with those who did (33% vs. 21%; P < .05).

Conclusions: Because of the relatively poor response to therapy, additional approaches to prevention and/or treatment of C. difficile colitis appear to be warranted.

Citing Articles

Synergistic and off-target effects of bacteriocins in a simplified human intestinal microbiome: implications for infection control.

Rios Colombo N, Ross R, Hill C Gut Microbes. 2025; 17(1):2451081.

PMID: 39817466 PMC: 11740676. DOI: 10.1080/19490976.2025.2451081.


Potential effectiveness of parenteral nemonoxacin in the treatment of infections: , , and mouse studies.

Lee C, Yan X, Wu H, Ko W, Tsai P, Hung Y Front Microbiol. 2024; 15:1418817.

PMID: 39228379 PMC: 11368742. DOI: 10.3389/fmicb.2024.1418817.


Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD.

Walsh L, Lavelle A, OConnor P, Hill C, Ross R Gut Microbes. 2024; 16(1):2342583.

PMID: 38722061 PMC: 11085969. DOI: 10.1080/19490976.2024.2342583.


Improving Infectious Disease Treatment Response via Adherence to Clinical Practice Guidelines.

Adukauskiene D, Mickus R, Dambrauskiene A, Vanagas T, Adukauskaite A Antibiotics (Basel). 2024; 13(1).

PMID: 38247610 PMC: 10812669. DOI: 10.3390/antibiotics13010051.


Antibiotic Resistances of Clostridioides difficile.

Spigaglia P, Mastrantonio P, Barbanti F Adv Exp Med Biol. 2024; 1435:169-198.

PMID: 38175476 DOI: 10.1007/978-3-031-42108-2_9.